Clinical Trials Logo
  1. Home
  2. Capecitabine
  3. NCT05970302

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Capecitabine Clinical Trial

Official title:
XELOX and Bevacizumab in Combination With Tislelizumab for First-Line Treatment of Patients With MSS/pMMR RAS-mutated Metastatic Colorectal Cancer (mCRC): A Single-arm, Phase II Study.

Clinical Trial Summary

The goal of this clinical trial is to compare XELOX +Bev +Tislelizumab with standard chemotherapy，in MSS/pMMR-type RAS-mutated metastatic colorectal adenocarcinoma. The main questions it aims to answer are efficacy and safety of the regimen of XELOX +Bev +Tislelizumab. The investigators want to transform ras-mutated colorectal cancer into a "hot tumor" through the combination of anti-vascular therapy and chemotherapy, and then achieve better therapeutic effect through the combination with immunotherapy. Participants will receive the regimen of XELOX +Bev +Tislelizumab.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05970302
Study type Interventional
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact
Status Recruiting
Phase Phase 2
Start date July 7, 2023
Completion date July 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT03079440 - TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors Phase 2
Completed NCT03079427 - Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma Phase 2
Recruiting NCT05290194 - Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma Phase 2
Not yet recruiting NCT03889626 - The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer Phase 3
Recruiting NCT06169202 - A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
Not yet recruiting NCT05841134 - Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer Phase 2
Recruiting NCT05022030 - First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes Phase 2
Recruiting NCT06202014 - Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC Phase 2
Enrolling by invitation NCT03030508 - Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients N/A
Recruiting NCT02012634 - Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer Phase 3
Active, not recruiting NCT06188000 - Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine N/A
Completed NCT06246461 - The Therapeutic Effect of Different Doses of Capecitabine N/A
Completed NCT04720131 - Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. Phase 2
Active, not recruiting NCT03258099 - Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Recruiting NCT05535413 - UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases Phase 1/Phase 2
Active, not recruiting NCT03500380 - A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases Phase 2/Phase 3
Recruiting NCT06405490 - NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC Phase 2